Investors

Press Releases

Press Releases

Date	Title
March 24, 2023	Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
March 9, 2023	Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
March 2, 2023	Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights
February 23, 2023	Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
February 21, 2023	Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
February 1, 2023	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2023	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 22, 2022	Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
December 2, 2022	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 22, 2022	Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax